Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma
An. bras. dermatol; 91 (3), 2016
Publication year: 2016
Abstract:
Immunosuppressive drugs and biological agents may represent a potential risk of lymphoma development in patients with rheumatoid arthritis. But most cases are diffuse, large B-cell lymphomas. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, a provisional entity in the 2005 WHO-EORTC classification of cutaneous lymphomas, is only described in a limited number of reports. To our knowledge, our case is a rare instance of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, after associated treatment with methotrexate and etanercept, in a patient with moderate rheumatoid arthritis who had undergone an orchidectomy incorrectly.
Etanercept/efectos adversos, Inmunosupresores/efectos adversos, Linfoma Cutáneo de Células T/inducido químicamente, Metotrexato/efectos adversos, Neoplasias Cutáneas/inducido químicamente, Artritis Reumatoide/tratamiento farmacológico, Linfoma Cutáneo de Células T/patología, Orquiectomía, Neoplasias Cutáneas/patología, Enfermedades Testiculares/diagnóstico, Enfermedades Testiculares/cirugía